News
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.
Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the ...
Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...
Investors betting against Viking Therapeutics (NASDAQ:VKTX) netted a one-day paper profit of $521M as the shares of the San ...
Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...
Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback